Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WTX-330 · 2 trials · 2 indications
RECIST = Response Evaluation Criteria in Solid Tumors
| Arm | Type | Description |
|---|---|---|
| Dose- and Regimen Finding | EXPERIMENTAL | Regimen 1 Fixed Dose for 28 days then Regimen 2 Step-up Dose for 28 days |
| Dose Expansion Arm A | EXPERIMENTAL | n\~20 Patients with locally advanced or metastatic cutaneous malignant melanoma who have been treated with a standard of care (SOC) checkpoint inhibitor (CPI) regimen and who demonstrate primary or secondary resistance to this therapy |
| Dose Expansion Arm B | EXPERIMENTAL | n\~20 Patients with locally advanced or metastatic microsatellite-stable (MSS) colorectal carcinoma (CRC) who have progressed on or are intolerant of SOC therapies and who are naïve to immunotherapy |
| Dose Expansion Arm C | EXPERIMENTAL | n\~20 Patients with advanced NHL who are relapsed/refractory to SOC therapies and who are CPI naïve |
| WTX-330 dose escalation | EXPERIMENTAL | Patients with relapsed/refractory advanced or metastatic solid tumors |
| WTX-330 dose expansion in patients for whom CPI therapy is indicated (Arm A) | EXPERIMENTAL | WTX-330 dose expansion in patients with tumor types for which a CPI is indicated/approved who demonstrate primary or secondary resistance to an anti-PD(L)1-based regimen |
| WTX-330 dose expansion in patients for whom CPI therapy is not indicated (Arm B) | EXPERIMENTAL | WTX-330 dose expansion in patients with tumor types for which a CPI is not indicated/ approved |
| Name | Type | Description |
|---|---|---|
| WTX-330 | DRUG | Investigational Product |
Inclusion Criteria: 1. Age ≥ 18 years, 2. Dose escalation (Part 1): Patients with relapsed/refractory locally advanced or metastatic solid tumor for which the patient has progressed on or is intolerant of standard therapy, or for whom no standard therapy with proven benefit exists. Patients with ca...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
WTX-330 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors and non-Hodgkin lymphoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
WTX-330 targets IL-2, a cytokine involved in immune signaling. By modulating IL-2 activity, the drug is designed to affect immune responses in the tumor microenvironment, though the exact mechanism is still under investigation.
WTX-330 is being developed by Werewolf Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol HOWL.
WTX-330 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied for safety and efficacy in clinical trials.
WTX-330 has been studied in two clinical trials. NCT05678998 was a completed Phase 1 study in patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma. NCT06939283 is an active Phase 1b/2 study in similar patient populations, with a planned enrollment of 100 participants.
WTX-330 is the primary name for this investigational drug. No alternative names have been reported in the clinical trial records, so it is not known to be identical to any other marketed or investigational agent.